Effects of chronic treatment with metformin on dipeptidyl peptidase‐4 activity, glucagon‐like peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus
- 7 April 2012
- journal article
- research article
- Published by Wiley in Diabetic Medicine
- Vol. 29 (8) , e205-e210
Abstract
Diabet. Med. 29, e205–e210 (2012) Aims Studies investigating the acute effects of metformin have demonstrated actions on the incretin system and appetite regulatory hormones. There are limited data to support that these effects are sustained in the long term. We therefore studied the effects of chronic treatment with metformin on endogenous glucagon‐like peptide 1, dipeptidyl peptidase‐4 activity and active ghrelin (an orexigenic hormone) in obese patients with Type 2 diabetes mellitus.Methods Eight subjects [six male, age 58.7 ± 2.6 years, BMI 41.1 ± 2.9 kg/m2, HbA1c 69 ± 6 mmol/mol (8.5 ± 0.5%), mean ± sem] with drug‐naïve Type 2 diabetes were studied for 6 h following a standard mixed meal, before and after at least 3 months of metformin monotherapy (mean dose 1.75 g daily).Results The area under the curve (AUC0–6 h) for active glucagon‐like peptide 1 was significantly higher on metformin (pre‐metformin 1750.8 ± 640 pmol l−1 min−1 vs. post‐metformin 2718.8 ± 1182.3 pmol l−1 min−1; P = 0.01). The areas under the curves for dipeptidyl peptidase‐4 activity and ghrelin were not significantly different pre‐ and post‐treatment with metformin.Conclusion Three months or more of metformin monotherapy in obese patients with Type 2 diabetes was associated with increased postprandial active glucagon‐like peptide 1 levels. The effects of metformin on the enteroinsular axis may represent yet another important mechanism underlying its glucose‐lowering effects.Keywords
This publication has 25 references indexed in Scilit:
- Addition of metformin to exogenous glucagon-like peptide–1 results in increased serum glucagon-like peptide–1 concentrations and greater glucose lowering in type 2 diabetes mellitusMetabolism, 2011
- Metformin increases plasma ghrelin in Type 2 diabetesBritish Journal of Clinical Pharmacology, 2009
- Investigation of the effect of oral metformin on dipeptidylpeptidase‐4 (DPP‐4) activity in Type 2 diabetes1Diabetic Medicine, 2009
- Metformin, but not pioglitazone, decreases postchallenge plasma ghrelin levels in type 2 diabetic patients: a possible role in weight stability?Diabetes, Obesity and Metabolism, 2008
- The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesThe Lancet, 2006
- Metformin prolongs the postprandial fall in plasma ghrelin concentrations in type 2 diabetesDiabetes/Metabolism Research and Reviews, 2006
- Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetesDiabetic Medicine, 2005
- Metformin Effects on Dipeptidylpeptidase IV Degradation of Glucagon-like Peptide-1Biochemical and Biophysical Research Communications, 2002
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998
- Effects of Metformin on Intestinal and Pancreatic Endocrine Secretion in Type 2 (Non-Insulin-Dependent) Diabetes1998